# EDGAR Filing Document

**Accession Number:** 0001178579
**File Stem:** 0001415889-25-021066
**Filing Date:** 2025-8
**Character Count:** 6732
**Document Hash:** 22b6ae695627137b78bfc5fda0a3b7cc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001415889-25-021066.hdr.sgml**: 20250805

**ACCESSION NUMBER**: 0001415889-25-021066

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250801

**FILED AS OF DATE**: 20250805

**DATE AS OF CHANGE**: 20250805

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** TANG KEVIN
- **CENTRAL INDEX KEY:** 0001178579

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36421
- **FILM NUMBER:** 251186329

**MAIL ADDRESS:**
- **STREET 1:** 4747 EXECUTIVE DRIVE
- **STREET 2:** SUITE 210
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**FORMER NAME:**
- **FORMER CONFORMED NAME:** TANG KEVIN C
- **DATE OF NAME CHANGE:** 20020723
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aurinia Pharmaceuticals Inc.
- **CENTRAL INDEX KEY:** 0001600620
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981231763
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** #140, 14315 - 118 AVENUE
- **CITY:** EDMONTON
- **STATE:** A0
- **ZIP:** T5L 4S6
- **BUSINESS PHONE:** 250-744-2487

**MAIL ADDRESS:**
- **STREET 1:** #140, 14315 - 118 AVENUE
- **CITY:** EDMONTON
- **STATE:** A0
- **ZIP:** T5L 4S6

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>TANG KEVIN<br><sub>(Last) (First) (Middle)</sub><br>4747 EXECUTIVE DR<br>SUITE 210<br><sub>(Street)</sub><br>SAN DIEGO, CA 92121<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-08-01 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Aurinia Pharmaceuticals Inc. [ AUPH ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Shares | 2025-08-01 |  | P |  | 1000000 | A | 10.12<sup>(1)</sup> | 11029500 | I | By LP<sup>(2)</sup> |
| Common Shares | 2025-08-04 |  | P |  | 100000 | A | 11.34<sup>(3)</sup> | 11129500 | I | By LP<sup>(2)</sup> |
| Common Shares | 2025-08-05 |  | P |  | 200000 | A | 11.68<sup>(4)</sup> | 11329500 | I | By LP<sup>(2)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $9.23 to $10.50. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1, 3 and 4.

(2) Tang Capital Partners, LP ("TCP") beneficially owns 6,371,711 shares and  Tang Capital Partners International, LP ("TCPI") beneficially owns 4,957,789 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP and TCPI.

(3) These shares were purchased in multiple transactions ranging from $11.11 to $11.48.

(4) These shares were purchased in multiple transactions ranging from $11.49 to $11.80.

**Signature:** Kevin Tang  
**Date:** 2025-08-05

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**